J&J, Sputnik V, Sinopharm jabs weaker against Omicron - study

Friday, 17. December 2021 13:09

Coronavirus vaccines developed by Johnson & Johnson and Sinopharm, as well as Russia's Sputnik V jab, produced almost no neutralizing activity against the Omicron variant, a study conducted by the University of Washington and Swiss drugmaker Humabs Biomed SA showed on Friday.

In a preprint published by bioRxiv, researchers noted that only one out of 12 individuals vaccinated with the J&J shot and three out of 13 who received the Sinopharm vaccine developed neutralizing antibodies against Omicron. Meanwhile, none of the 11 people who were vaccinated with Sputnik had such antibodies, contradicting claims made by Russian President Vladimir Putin who stated the vaccine retains efficacy against Omicron. People who were vaccinated with Moderna, Pfizer or AstraZeneca jabs "retained activity against Omicron with a decrease of 33-, 44- and 36-fold, respectively."

"Collectively, these findings demonstrate a substantial and unprecedented reduction in plasma neutralizing activity against Omicron versus the ancestral virus, that in several cases may fall below protective titers," the scientists concluded.

Related Links: Johnson & JohnsonAstraZeneca plc
Baha Breaking News (BBN) / NP